Included in the Morgan Stanley Capital International (MSCI) China Index
2022-07-08

Included in the Morgan Stanley Capital International (MSCI) China Index

Ranked in the list of Forbes on ”Asia’s Best 200 Enterprises Under a Billion”

Ranked in the list of Forbes on ”Asia’s Best 200 Enterprises Under a Billion”

Won “The Listed Company with the Best Information Disclosure” of the “China Securities Golden Bauhinia Award” held by Ta Kung Pao

Won “The Listed Company with the Best Information Disclosure” of the “China Securities Golden Bauhinia Award” held by Ta Kung Pao

Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)”

Tianjing Kangzhe was awarded the “Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)”

Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen”

Shenzhen Kangzhe was awarded the “Top 100 Enterprises in Shenzhen”

Became the largest shareholder of Tibet Rhodiola Pharmaceutical with a total of 26.61% equity interest

Became the largest shareholder of Tibet Rhodiola Pharmaceutical with a total of 26.61% equity interest

Acquired assets of Augentropfen Stulln Mono Eye-drops, MOVICOL® and Parlodel® in Mainland China and/or other countries or regions

Acquired assets of Augentropfen Stulln Mono Eye-drops, MOVICOL® and Parlodel® in Mainland China and/or other countries or regions